Albumin: Not just a plasma expander

Ascites, Hyponatremia and Hepatorenal Syndrome: Progress in Treatment

Volumn 28, Issue , 2010, Pages 40-51

  Davies, Nathan A ^a   Garcia, Rita ^a   Proven, Andrew ^a   Jalan, Rajiv ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874918418     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000319177     Document Type: Chapter

References (39)

1. Evans TW: Albumin as a drug-biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 2002;16(suppl 5):6-11.
2. Peters T: All About Albumin: Biochemistry, Genetics, and Medical Applications. San Diego, Academic Press, 1996.
3. Sort P, Navasa M, Arroyo V, et al: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-409.
4. Runyon BA: Management of adult patients with ascites due to cirrhosis. Hepatology 2004;39:841-856.
5. Ortega R, Gines P, Uriz J, Cardenas A, et al: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002;36:941-948.
6. Neri S, Pulvirenti D, Malaguarnera M, et al: Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 2008; 53:830-835.
7. Sanyal AJ, Boyer T, Garcia-Tsao G, et al: A randomized, prospective, double- blind, placebo- controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-1368.
8. Martin-Llahi M, Pepin MN, Guevara M, et al: Terlipressin and albumin vs. albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-1359.
9. Gines P, Tito L, Arroyo V, et al: Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988;94:1493-1502.
10. Planas R, Gines P, Arroyo V, et al: Dextran- 70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology 1990;99:1736-1744.
11. Garcia-Compean D, Blanc P, Larrey D, et al: Treatment of cirrhotic tense ascites with Dextran- 40 versus albumin associated with large volume paracentesis: a randomized controlled trial. Ann Hepatol 2002;1:29-35.
12. Luca A, Garcia-Pagan JC, Bosch J, et al: Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology 1995;22:753-758.
13. Gines A, Fernandez-Esparrach G, Monescillo A, et al: Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111: 1002-1010.
14. Sola-Vera J, Minana J, Ricart E, et al: Randomized trial comparing albumin and saline in the prevention of paracentesis- induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003;37:1147-1153.
15. Appenrodt B, Wolf A, Grunhage F, et al: Prevention of paracentesis- induced circulatory dysfunction: midodrine vs. albumin-a randomized pilot study. Liver Int 2008;28:1019-1025.
16. Umgelter A, Reindl W, Wagner KS, et al: Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial. Crit Care 2008;12:R4.
17. Fernandez J, Navasa M, Garcia-Pagan JC, et al: Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol 2004;41: 384-390.
18. Jalan R, Kapoor D: Reversal of diuretic- induced hepatic encephalopathy with infusion of albumin but not colloid. Clin Sci (Lond) 2004;106:467-474.
19. Hassanein TI, Tofteng F, Brown RS Jr, et al: Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007;46:1853-1862.
20. Chen TA, Tsao YC, Chen A, et al: Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scand J Gastroenterol 2009;44:619-625.
21. Stadlbauer V, Mookerjee RP, Wright GA, et al: Role of Toll- like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol 2009;296:G15-G22.
22. Sen S, Mookerjee RP, Cheshire LM, Davies NA, Williams R, Jalan R: Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol 2005;43:142-148.
23. Cochrane Injuries Group Albumin Reviewers: Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ 1998;317:235-240.
24. Wilkes MM, Navickis RJ: Patient survival after human albumin administration: a meta- analysis of randomized, controlled trials. Ann Intern Med 2001;135:149-164.
25. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350:2247-2256.
26. Idicula TT, Waje-Andreassen U, Brogger J, Naess H, Thomassen L: Serum albumin in ischemic stroke patients: the higher the better. The Bergen Stroke Study. Cerebrovasc Dis 2009;28:13-17.
27. Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD: Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001; 32:553-560.
28. Koch S, Concha M, Wazzan T, Romano JG, Forteza A: High dose human serum albumin for the treatment of acute ischemic stroke: a safety study. Neurocrit Care 2004;1:335-341.
29. Palesch YY, Hill MD, Ryckborst KJ, Tamariz D, Ginsberg MD: The ALIAS Pilot Trial: a doseescalation and safety study of albumin therapy for acute ischemic stroke. II. Neurologic outcome and efficacy analysis. Stroke 2006;37:2107-2114.
30. Maitland K, Pamba A, English M, et al: Randomized trial of volume expansion with albumin or saline in children with severe malaria: preliminary evidence of albumin benefit. Clin Infect Dis 2005;40:538-545.
31. Sedrakyan A, Gondek K, Paltiel D, Elefteriades JA: Volume expansion with albumin decreases mortality after coronary artery bypass graft surgery. Chest 2003;123:1853-1857.
32. Engelman DT, Adams DH, Byrne JG, et al: Impact of body mass index and albumin on morbidity and mortality after cardiac surgery. J Thorac Cardiovasc Surg 1999;118:866-873.
33. Magovern JA, Sakert T, Magovern GJ, et al: A model that predicts morbidity and mortality after coronary artery bypass graft surgery. J Am Coll Cardiol 1996; 28:1147-1153.
34. Goldwasser P, Feldman J: Association of serum albumin and mortality risk. J Clin Epidemiol 1997; 50:693-703.
35. Lawrence A, Faraklas I, Watkins H, et al: Colloid administration normalizes resuscitation ratio and ameliorates 'fluid creep'. J Burn Care Res 2010;31:40-47.
36. Chen LW, Wang JS, Hwang B, Chen JS, Hsu CM: Reversal of the effect of albumin on gut barrier function in burn by the inhibition of inducible isoform of nitric oxide synthase. Arch Surg 2003;138: 1219-1225.
37. Visser M, Kritchevsky SB, Newman AB, et al: Lower serum albumin concentration and change in muscle mass: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005;82:531-537.
38. Jalan R, Schnurr K, Mookerjee RP, et al: Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 2009;50:555-564.
39. Quinlan GJ, Martin GS, Evans TW: Albumin: biochemical properties and therapeutic potential. Hepatology 2005;41:1211-1219.